Comparative Pharmacology
Head-to-head clinical analysis: EMPAGLIFLOZIN AND LINAGLIPTIN versus ONGLYZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMPAGLIFLOZIN AND LINAGLIPTIN versus ONGLYZA.
EMPAGLIFLOZIN AND LINAGLIPTIN vs ONGLYZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor that reduces renal glucose reabsorption, increasing urinary glucose excretion. Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormones (GLP-1, GIP), enhancing insulin secretion and decreasing glucagon levels.
Selective inhibitor of dipeptidyl peptidase-4 (DPP-4), increasing incretin hormones (GLP-1, GIP) to enhance glucose-dependent insulin secretion and suppress glucagon release.
10 mg empagliflozin / 5 mg linagliptin orally once daily
2.5 mg or 5 mg orally once daily
None Documented
None Documented
Empagliflozin: terminal half-life ~12.4 hours, allowing once-daily dosing. Linagliptin: terminal half-life ~113-131 hours due to saturable binding to DPP-4, enabling once-daily dosing despite short plasma half-life.
Terminal elimination half-life is approximately 12.4 hours for saxagliptin. The half-life of its active metabolite is about 2.1 hours. The pharmacologically relevant half-life supports once-daily dosing.
Empagliflozin: 54% excreted unchanged in urine (renal), 41% in feces (biliary/fecal). Linagliptin: 80% excreted unchanged in feces via enterohepatic circulation, <5% in urine.
Approximately 75% of the administered dose is excreted in urine, with about 21% recovered as parent drug, and the remainder as metabolites. Fecal excretion accounts for about 22% of the dose, primarily as parent drug and metabolites.
Category A/B
Category C
DPP-4 Inhibitor
DPP-4 Inhibitor